NDAINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSPOWDER
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
GLUCAGON (glucagon) by Fresenius Kabi is stomach, small bowel, and colon. Approved for type 1 diabetes mellitus, hypoglycemia. First approved in 2015.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Glucagon is a hormone-based injectable powder approved for acute treatment of severe hypoglycemia in Type 1 diabetes patients. It works by stimulating glycogen breakdown and glucose release from the liver via glucagon receptor activation in the stomach, small bowel, and colon. The drug is administered via intramuscular, intravenous, or subcutaneous injection.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30/100), suggesting stable commercial operations but limited growth headroom for expanding teams.
Mechanism of Action
stomach, small bowel, and colon.
Indications (2)
Clinical Trials (20)
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
Started Apr 2026
50 enrolled
Laxity; Skin
Glucagon Resistance in Patients With MASLD and T2DM
Started Jan 2026
24 enrolled
Metabolic Associated Fatty Liver DiseaseType 2 Diabetes (T2DM)
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
Started Nov 2025
24 enrolled
Wrinkle
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Started Oct 2025
10 enrolled
glp1 AgonistGene ExpressionSkin Laxity
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
Started Mar 2025
126 enrolled
Autosomal Dominant Polycystic KidneyObesity
Worked on GLUCAGON at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.